



New Summary Report - 31 March 2015

1. In the past six months approximately how many times have you experienced an instance of a large upswing in the acquisition price of a generic drug?




				Statistics	
Never	0.1%	<div style="width: 0.1%; height: 10px; background-color: #cccccc;"></div>	1	Sum	13,960.0
1-25 instances	18.3%	<div style="width: 18.3%; height: 10px; background-color: #1f77b4;"></div>	128	Average	27.4
26-50 instances	32.3%	<div style="width: 32.3%; height: 10px; background-color: #2ca02c;"></div>	226	StdDev	18.6
51-100 instances	22.3%	<div style="width: 22.3%; height: 10px; background-color: #ff7f0e;"></div>	156	Max	51.0
More than 100 instances	27.0%	<div style="width: 27.0%; height: 10px; background-color: #d62728;"></div>	189		
Total			700		

2. Since 2013, how would you say this situation of generic drug price spikes has changed?



Improved	0.4%		3
Gotten worse	93.4%		652
About the same – no improvement or degradation	6.2%		43
Total			698

In those situations since 2013 in which you have experienced a dramatic upswing in the acquisition price of a generic drug, on average, how long did it take the PBMs or other third party payers to correspondingly update pharmacy reimbursement rates?




Immediately (provided retroactive adjustment)	0.0%		0
1-2 weeks	0.3%		2
3 weeks	2.2%		15
1-2 months	24.7%		171
3 months or more	62.3%		432
Never	10.5%		73
Total			693

Statistics


Sum	1,514.0
Average	2.4
StdDev	0.9
Max	3.0

3. When PBMs do not update generic drug reimbursement rates to reflect price inflation, community pharmacies absorb financial losses on these prescriptions. Since 2013, how would you say this situation has changed?



Improved	0.1%		1
Gotten worse	92.8%		644
About the same – no improvement or degradation	7.1%		49
Total			694

4. When you or your contracting entity (such as a PSAO) appeals to PBMs to fix MAC underpayments for rising generic drug costs, what is the typical response from the PBMs?



The MAC is adjusted, but not retroactively	13.3%		92
Appeal is rejected; the MAC remains below cost	56.9%		394
Total			692

No response from the PBMs at all	25.9%		179
I do not usually appeal below-cost MACs on generic drugs that surge in price	3.9%		27
Total			692